

# Jonathan N Townend

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5210852/publications.pdf>

Version: 2024-02-01

87  
papers

3,791  
citations

186265  
28  
h-index

128289  
60  
g-index

90  
all docs

90  
docs citations

90  
times ranked

6356  
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 514-525.	11.4	604
2	Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2009, 54, 505-512.	2.8	256
3	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. <i>BMJ</i> , 2015, 351, h4451.	6.0	247
4	Nitric Oxide and Cardiac Autonomic Control in Humans. <i>Hypertension</i> , 2000, 36, 264-269.	2.7	148
5	Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. <i>BMC Nephrology</i> , 2016, 17, 127.	1.8	134
6	Role of nitric oxide in the regulation of cardiovascular autonomic control. <i>Clinical Science</i> , 1999, 97, 5-17.	4.3	128
7	Arterial stiffness in chronic kidney disease: causes and consequences. <i>Heart</i> , 2010, 96, 817-823.	2.9	124
8	Arterial disease in chronic kidney disease. <i>Heart</i> , 2013, 99, 365-372.	2.9	119
9	Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2497.	7.4	118
10	Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	116
11	The haemodynamic effects of adjunctive hormone therapy in potential heart donors: a prospective randomized double-blind factorially designed controlled trial. <i>European Heart Journal</i> , 2009, 30, 1771-1780.	2.2	111
12	Mechanical effects of left ventricular midwall fibrosis in non-ischemic cardiomyopathy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, 1.	3.3	111
13	Cardiovascular Effects of Sevelamer in Stage 3 CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 842-852.	6.1	108
14	Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: Cause or association?. <i>Atherosclerosis</i> , 2012, 223, 86-94.	0.8	107
15	Quantification of Left Ventricular Interstitial Fibrosis in Asymptomatic Chronic Primary Degenerative Mitral Regurgitation. <i>Circulation: Cardiovascular Imaging</i> , 2014, 7, 946-953.	2.6	92
16	Defining the Natural History of Uremic Cardiomyopathy in Chronic Kidney Disease. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 703-714.	5.3	92
17	Comparison of magnetic resonance feature tracking for systolic and diastolic strain and strain rate calculation with spatial modulation of magnetization imaging analysis. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 1000-1012.	3.4	87
18	Diffuse Interstitial Fibrosis and Myocardial Dysfunction in Early Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2015, 115, 1311-1317.	1.6	87

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors. <i>Hypertension</i> , 2016, 67, 368-377.	2.7	85
20	Atrial Fibrillation in CKD: Balancing the Risks and Benefits of Anticoagulation. <i>American Journal of Kidney Diseases</i> , 2013, 62, 615-632.	1.9	69
21	Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2576-2582.	0.7	64
22	Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. <i>Heart</i> , 2012, 98, 219-224.	2.9	64
23	Effect of Spironolactone on Left Ventricular Systolic and Diastolic Function in Patients With Early Stage Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2010, 106, 1505-1511.	1.6	55
24	The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 447-454.	2.4	55
25	Echocardiography in the Potential Heart Donor. <i>Transplantation</i> , 2010, 89, 894-901.	1.0	51
26	Coronary Artery Calcium Assessment in CKD: Utility in Cardiovascular Disease Risk Assessment and Treatment?. <i>American Journal of Kidney Diseases</i> , 2015, 65, 937-948.	1.9	37
27	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. <i>BMJ Open</i> , 2017, 7, e015099.	1.9	37
28	Cytomegalovirus Seropositivity Is Associated with Increased Arterial Stiffness in Patients with Chronic Kidney Disease. <i>PLoS ONE</i> , 2013, 8, e55686.	2.5	33
29	Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial: a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25Åmg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 160.	1.6	29
30	Defining Myocardial Abnormalities Across the Stages of Chronic Kidney Disease. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2357-2367.	5.3	27
31	Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy?. <i>Heart</i> , 2019, 105, 1302-1309.	2.9	24
32	Early effects of kidney transplantation on the heart - A cardiac magnetic resonance multi-parametric study. <i>International Journal of Cardiology</i> , 2019, 293, 272-277.	1.7	21
33	Clinical Potential of Targeting Fibroblast Growth Factorâ€³ and Î±Klotho in the Treatment of Uremic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2020, 9, e016041.	3.7	20
34	The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. <i>Clinical Endocrinology</i> , 2010, 73, 566-572.	2.4	19
35	Does immunosuppressant medication lower blood pressure and arterial stiffness in patients with chronic kidney disease? An observational study. <i>Hypertension Research</i> , 2011, 34, 113-119.	2.7	17
36	Effects of age and chronic kidney disease on regional aortic distensibility: A cardiovascular magnetic resonance study. <i>International Journal of Cardiology</i> , 2013, 168, 4249-4254.	1.7	17

#	ARTICLE	IF	CITATIONS
37	Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 599-613.	1.7	17
38	Prognostic Utility of Calcium Scoring as an Adjunct to Stress Myocardial Perfusion Scintigraphy in End-Stage Renal Disease. <i>American Journal of Cardiology</i> , 2016, 117, 1387-1396.	1.6	17
39	Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial. <i>BMJ Open</i> , 2016, 6, e010519.	1.9	16
40	Republished paper: Arterial stiffness in chronic kidney disease: causes and consequences. <i>Postgraduate Medical Journal</i> , 2010, 86, 560-566.	1.8	15
41	Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: Rationale and design of the EARNEST study. <i>American Heart Journal</i> , 2014, 167, 141-149.e2.	2.7	15
42	Endothelial Nitric Oxide Synthase Single Nucleotide Polymorphism and Left Ventricular Function in Early Chronic Kidney Disease. <i>PLoS ONE</i> , 2015, 10, e0116160.	2.5	15
43	Chronic kidney disease as a cardiovascular risk factor: lessons from kidney donors. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 497-505.e4.	2.3	13
44	Arterial stiffness in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 527-536.	2.0	11
45	Changes in left ventricular structure and function associated with renal transplantation: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2021, 8, 2045-2057.	3.1	11
46	Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. <i>Trials</i> , 2011, 12, 30.	1.6	10
47	Aortic Calcification and Femoral Bone Density Are Independently Associated with Left Ventricular Mass in Patients with Chronic Kidney Disease. <i>PLoS ONE</i> , 2012, 7, e39241.	2.5	10
48	Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1140-1144.	0.7	10
49	A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial. <i>American Heart Journal</i> , 2017, 191, 37-46.	2.7	10
50	Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial. <i>Trials</i> , 2014, 15, 158.	1.6	9
51	Changes in Blood Pressure and Arterial Hemodynamics following Living Kidney Donation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1330-1339.	4.5	9
52	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors at 5 Years. <i>Hypertension</i> , 2021, 77, 1273-1284.	2.7	8
53	Phosphate: are we squandering a scarce commodity?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 163-168.	0.7	7
54	Sudden cardiac death in chronic renal disease: aetiology and risk reduction strategies. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1386-1388.	0.7	7

#	ARTICLE	IF	CITATIONS
55	Myocardial characterization in pre-dialysis chronic kidney disease: a study of prevalence, patterns and outcomes. BMC Cardiovascular Disorders, 2019, 19, 295.	1.7	7
56	Improving the diagnosis of heart failure in patients with atrial fibrillation. Heart, 2021, 107, 902-908.	2.9	7
57	Measuring frailty in patients undergoing TAVI: how and why?. European Heart Journal, 2019, 40, 2240-2242.	2.2	6
58	Comparison of Routine Versus Selective Glycoprotein IIb/IIIa Inhibitors Usage in Primary Percutaneous Coronary Intervention (from the British Cardiovascular Interventional Society). American Journal of Cardiology, 2019, 124, 373-380.	1.6	6
59	Coronary flow velocity reserve and inflammatory markers in living kidney donors. International Journal of Cardiology, 2020, 320, 141-147.	1.7	6
60	Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, CJN.01930221.	4.5	6
61	Mitral Regurgitation Following Acute Myocardial Infarction Treated by Percutaneous Coronary Intervention—Prevalence, Risk factors, and Predictors of Outcome. American Journal of Cardiology, 2021, 157, 22-32.	1.6	5
62	Results of Serial Myocardial Perfusion Imaging in End-Stage Renal Disease. American Journal of Cardiology, 2018, 121, 661-667.	1.6	4
63	Impaired circumferential and longitudinal myocardial deformation in early stage chronic kidney disease: the earliest features of uremic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2013, 15, .	3.3	3
64	What is the cause of hypotension? A rare complication of percutaneous coronary intervention of a chronic total occlusion: a case report. European Heart Journal - Case Reports, 2019, 3, 1-5.	0.6	3
65	Screening for occult coronary artery disease in potential kidney transplant recipients: time for reappraisal?. CKJ: Clinical Kidney Journal, 2021, 14, 2472-2482.	2.9	3
66	Risk for subsequent hypertension and cardiovascular disease after living kidney donation: is it clinically relevant?. CKJ: Clinical Kidney Journal, 2022, 15, 644-656.	2.9	3
67	Acute Presentation of Structural Valve Degeneration in a Transcatheter Heart Valve (Sapien XT) at 7.5 Years; Successful Redo TAVR With a Sapien 3 Ultra. CJC Open, 2021, 3, 383-386.	1.5	2
68	Upregulation of the Nitric Oxide-cGMP Pathway in Aged Myocardium. Circulation Research, 2001, 88, E48.	4.5	1
69	SPRINTing towards trials of blood pressure reduction to reduce CKD progression?. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 229-230.	4.0	1
70	10â€¦Cardiac alterations after renal transplant; controversies unravelled by cardiac mri. Heart, 2017, 103, A6-A7.	2.9	1
71	11â€¦Cpex testing detects subclinical cardiac limitation to exercise in early stage ckd. Heart, 2017, 103, A7.1-A7.	2.9	1
72	CKD Associated Cardiomyopathy: Molecular Mechanisms, Imaging Modalities, Disease Evolution and Interventions. , 2017, , 45-58.		1

#	ARTICLE	IF	CITATIONS
73	The characteristics of mitral regurgitation: Data from patients admitted following acute myocardial infarction. Data in Brief, 2021, 39, 107451.	1.0	1
74	Changing trends in the incidence, management and outcomes of coronary artery perforation over an 11-year period: single-centre experience. Open Heart, 2022, 9, e001916.	2.3	1
75	Letter by Moody et al Regarding Article "Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction" Circulation, 2012, 126, e62; author reply e64-5.	1.6	0
76	The EARNEST Study: Interarm blood pressure differences should also be recorded. American Heart Journal, 2014, 168, e9.	2.7	0
77	37"Cardiovascular Effects of Unilateral Nephrectomy in Human Kidney Donors. Heart, 2015, 101, A20.2-A21.	2.9	0
78	MP387CARDIAC LIMITATION OCCURS EARLY IN CKD, AND CANNOT BE FULLY EXPLAINED BY ISCHAEMIA OR REDUCED LV COMPLIANCE AS MEASURED BY DIASTOLIC FUNCTION DURING EXERCISE. Nephrology Dialysis Transplantation, 2017, 32, iii570-iii570.	0.7	0
79	MP392CARDIOPULMONARY EXERCISE TESTING DETECTS SUBCLINICAL CARDIAC LIMITATION TO EXERCISE IN EARLY STAGE CKD. Nephrology Dialysis Transplantation, 2017, 32, iii572-iii572.	0.7	0
80	24"Myocardial tissue characterisation in progressive CKD: is diffuse interstitial fibrosis the key intermediary of uraemic cardiomyopathy?. , 2018, , .		0
81	72"Out-of-hospital cardiac arrest survivors undergoing emergency PCI have an excellent neurological recovery. , 2019, , .		0
82	73"Outcomes in patients undergoing percutaneous coronary intervention with chronic kidney disease. , 2019, , .		0
83	Vive les Differences!"A case for optimism in the treatment of patients with heart failure and preserved ejection fraction?. International Journal of Clinical Practice, 2019, 73, e13307.	1.7	0
84	P0254MYOCARDIAL TISSUE CHARACTERIZATION IN LIVING KIDNEY DONORS 5 YEARS AFTER NEPHRECTOMY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
85	Contemporary use of excimer laser in percutaneous coronary intervention with indications, procedural characteristics, complications and outcomes in a university teaching hospital. Open Heart, 2021, 8, e001522.	2.3	0
86	A Longitudinal Study of Mitral Regurgitation Detected after Acute Myocardial Infarction. Journal of Clinical Medicine, 2022, 11, 965.	2.4	0
87	Antithrombotic treatment following coronary artery bypass surgery: a network meta-analysis. The Cochrane Library, 2021, 2021, .	2.8	0